Citius Pharmaceuticals
CTXR
42 hedge funds and large institutions have $822K invested in Citius Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
11% more funds holding
Funds holding: 38 → 42 (+4)
0.5% more ownership
Funds ownership: 4.46% → 4.95% (+0.5%)
8% less capital invested
Capital invested by funds: $897K → $822K (-$74.5K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$84.6K |
| 2 |
MFS
Miller Financial Services
Marshall,
Michigan
|
+$78.5K |
| 3 |
Jane Street
New York
|
+$67.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$25.7K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$54K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$19.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
| 5 |
Citigroup
New York
|
-$4.71K |
CTXR Hedge Fund Activity: Q2 2026 in Review
42 of the 8,331 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2026, worth a combined $822K — down 8.3% from $897K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CTXR positions and 8 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $84.6K. The largest seller was HRT Financial, exiting entirely with an estimated $54K sold.
- 42 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2026, up from 38 in Q1 2026.
- Funds reported $822K of Citius Pharmaceuticals stock for Q2 2026, down 8.3% quarter-over-quarter.
- 12 funds opened new Citius Pharmaceuticals positions in Q2 2026 and 8 closed out, a net change of +4 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2026 was Citadel Advisors, an estimated $84.6K added.
- The largest Citius Pharmaceuticals seller in Q2 2026 was HRT Financial, an estimated $54K sold.
Based on aggregated 13F filings for Q2 2026.